PDF(Pubmed)
Abstract：
Malaria caused by the Plasmodium vivax parasite is a major global health burden. Immunity against blood-stage infection reduces parasitemia and disease severity. Duffy-binding protein (DBP) is the primary parasite protein responsible for the invasion of red blood cells and it is a leading subunit vaccine candidate. An effective vaccine, however, is still lacking despite decades of interest in DBP as a vaccine candidate. This review discusses the reasons for targeting DBP, the challenges associated with developing a vaccine, and modern structural vaccinology methods that could be used to create an effective DBP vaccine. Next-generation DBP vaccines have the potential to elicit a broadly protective immune response and provide durable and potent protection from P. vivax malaria.
摘要：
间日疟原虫寄生虫引起的疟疾是全球主要的健康负担。对血液阶段感染的免疫力可降低寄生虫血症和疾病严重程度。Duffy结合蛋白（DBP）是负责侵入红细胞的主要寄生虫蛋白，并且是主要的亚单位疫苗候选物。一种有效的疫苗，然而,尽管数十年来人们对DBP作为候选疫苗的兴趣仍然缺乏。这篇综述讨论了以DBP为目标的原因，与开发疫苗相关的挑战，以及可用于创建有效DBP疫苗的现代结构疫苗学方法。下一代DBP疫苗有可能引发广泛的保护性免疫反应，并提供持久和有效的间日疟原虫保护。
